MedTrace Logo

H-IVIG Treatment for Severe H1N1 2009

NCT01617317 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2012-06-12

No results posted yet for this study

Summary

Treatment with hyperimmune intravenous immunoglobulin (H-IVIG), derived from convalescent plasma from patients recovered from H1N1 2009 influenza A infection, for patients with severe H1N1 2009 infection will decrease mortality, reduce viral load, and shorten the length of stay in ICU and hospital.

Conditions

  • Novel 2009 Influenza A (H1N1) Infection

Interventions

DRUG

Hyperimmune intravenous immunoglobulin

Single intravenous infusion of 0.4g/kg of H1N1 2009 H-IVIG

DRUG

Intravenous immunoglobulin

Single intravenous infusion of 0.4g/kg of simple IVIG

Sponsors & Collaborators

  • Queen Mary Hospital, Hong Kong

    collaborator OTHER

  • Pamela Youde Nethersole Eastern Hospital

    collaborator OTHER

  • Ruttonjee Hospital, Hong Kong

    collaborator UNKNOWN

  • United Christian Hospital

    collaborator OTHER

  • Queen Elizabeth Hospital, Hong Kong

    collaborator OTHER

  • Caritas Medical Centre, Hong Kong

    collaborator OTHER

  • HK Red Cross Blood Transfusion Service, Hong Kong

    collaborator UNKNOWN

  • Research Fund for the Control of Infectious Diseases, Hong Kong

    collaborator UNKNOWN

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Ivan FN Hung, MD FRCP · The University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2011-11-30
Completion
2012-05-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01617317 on ClinicalTrials.gov